Patients who survive acute respiratory distress syndrome (ARDS) often leave a hospital intensive care unit with debilitating mental, physical, or cognitive problems that may limit their quality of life
People who are diagnosed with coronary artery disease and then develop depression face a risk of death that’s twice as high as heart patients without depression, according to a major new study by researchers at Intermountain Healthcare in Salt Lake City.
Many patients with melanoma need a sentinel-lymph-node biopsy to determine if cancer cells have spread there, but a positive finding doesn’t mean all the lymph nodes in the area must be removed, according to a new international study.
Patients with hepatitis C who suffer from advanced stages of liver disease have renewed hope, thanks to findings by researchers who have discovered that a new drug significantly reduces their risk of death and need for transplantation.
Despite many advancements in liver transplantation — like the cure for the hepatitis C virus — liver disease continues to impact people of all ages and cultures across the globe.
A new study by researchers at the Intermountain Medical Center Heart Institute in Salt Lake City found that using long-term aspirin therapy to prevent strokes among patients who are considered to be at low risk for stroke may not be effective as previously thought.
A new study has found that dementia rates increase when anticoagulation treatment is delayed for patients with atrial fibrillation, the most common heart arrhythmia in the world that affects more than 2.7 million American adults.
Researchers have identified a microRNA biomarker that demonstrates a strong association with the incidence of atrial fibrillation, the most common abnormal heart rhythm.
Combining the Intermountain Mortality Risk Score (IMRS), developed by clinicians at Intermountain Healthcare, with the traditional CHA2DS2-VASc risk score, was more accurate in identifying at-risk patients than using the traditional score alone.
By combining a patient’s traditional risk score with the Intermountain Mortality Risk Score (IMRS), physicians and patients are better equipped to evaluate a patient’s individual risk of stroke, bleeding, and mortality with atrial fibrillation, according to a new study of more than 80,000 patients from the Intermountain Medical Center Heart Institute in Salt Lake City.
A novel treatment offers kidney failure and kidney transplant patients with a rare disorder new hope. The treatment allows targeted elimination of plasma cell clones producing abnormal proteins that deposits in the kidneys and leads to kidney failure, according to new research.
Researchers have discovered that a new anti-rejection drug that is gentler on the kidneys after liver transplant also reduces weight gain, which is common after surgery and can lead to serious problems for transplant patients.
Hearst Health, a division of Hearst, and the Jefferson College of Population Health of Thomas Jefferson University, have announced that Utah-based Intermountain Healthcare is the winner of the 2017 Hearst Health Prize.
Researchers are revisiting their views on the relative dangers soft and hard atherosclerotic plaque deposits pose to heart health. Findings of a new study by researchers at the Intermountain Medical Center Heart Institute may be a “game-changer” for determining who’s at risk of a heart attack, they say.
Ablation procedures restore a regular heartbeat in patients who have a dangerous, abnormal heart rhythm called atrial fibrillation. But it doesn’t always work. Now, a new study suggests that certain molecules are associated with the recurrence of erratic heartbeats in some patients after ablation therapy.
Combining two independent, scientifically-proven risk measurements allows physicians to better predict an atrial fibrillation patient’s risk of stroke or death. The tools also help determine the need for blood thinners in treatment, according to new research from researchers at the Intermountain Medical Center Heart Institute in Salt Lake City.
Findings from a large, community-based study show that antithrombotic therapy doesn’t decrease low-risk atrial fibrillation patients’ risk of suffering a stroke within five years. In fact, researchers found that low-risk patients fared better without any antithrombotic therapy.
A new study by researchers at the Intermountain Medical Center Heart Institute in Salt Lake City finds that combining information from routine blood tests and age of primary care patients can create a score that measures future risk of chronic disease.
New research suggests that GlycA, a newly identified blood marker, and C-reactive protein both independently predict major adverse cardiac events, including heart failure and death. Patients who have high levels of both biomarkers are at especially high risk.
Depression is the strongest predictor of death in the first decade following a diagnosis of coronary heart disease, according to a new study by researchers at the Intermountain Medical Center Heart Institute in Salt Lake City.
RSS
Medicine keyboard_arrow_right
Sciencekeyboard_arrow_right
Life keyboard_arrow_right
Business keyboard_arrow_right
Journal News keyboard_arrow_right
By Location keyboard_arrow_right
Meetings, Grants, and Events keyboard_arrow_right